CMS in 2022 will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for many hospitals’ 340B-purchased drugs and biologicals.

News Alert: CMS Will Continue Deep Cut in 340B Hospitals’ Medicare Part B Drug Reimbursement

In a big disappointment for 340B hospital organizations, the U.S. Centers for Medicare & Medicaid Services (CMS) announced late this afternoon that it will continue a nearly 30% reduction in place since 2018 in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs and biologicals for 2022.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
×